Medical Supplies

Henry Schein Announces $400 Million Increase to Share Repurchase Plan

Thursday, May 13, 2021 - 10:05pm

This new authorization represents approximately 4.0 percent of shares outstanding at the current stock price.

Key Points: 
  • This new authorization represents approximately 4.0 percent of shares outstanding at the current stock price.
  • With more than 20,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes.
  • All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance.
  • We undertake no duty and have no obligation to update forward-looking statements.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513006041/en/\n"

Procaps Group Reports Record First Quarter 2021 Financial Results

Thursday, May 13, 2021 - 9:01pm

Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.

Key Points: 
  • Procaps Group expects full-year Adjusted EBITDA margin expansion from 22% in 2019 to 26% in 2021 with strong positive free cash flow.
  • Procaps has a direct presence in 13 countries in Latin America and has more than 5,000 collaborators working under a sustainable model.
  • Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.
  • A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements.

Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company

Thursday, May 13, 2021 - 4:30pm

b'Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company, and #2 in overall corporate reputation among U.S. patient groups familiar with the company.

Key Points: 
  • b'Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company, and #2 in overall corporate reputation among U.S. patient groups familiar with the company.
  • \xe2\x80\x9cTo be recognized by these patient groups who we have learned so much from \xe2\x80\x93 and whose insights have guided nearly every facet of our work \xe2\x80\x93 is an honor.
  • The company ranked #2 for supporting patients during the COVID-19 pandemic, patient centricity and quality of relationships with patient groups.\nAmong patient groups familiar with the company, Horizon ranked #4 in overall reputation and #2 for companies acting with integrity.
  • Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients.

First Nation Group Announces Launch of Pharmaceuticals Division

Thursday, May 13, 2021 - 3:02pm

b'First Nation Group , the premier Service-Disabled Veteran-Owned Small Business, Women-Owned Small Business, and HUBZone Small Business medical-surgical distributor to the Federal Government, announced today a new pharmaceutical division, First Nation Pharmaceuticals .

Key Points: 
  • b'First Nation Group , the premier Service-Disabled Veteran-Owned Small Business, Women-Owned Small Business, and HUBZone Small Business medical-surgical distributor to the Federal Government, announced today a new pharmaceutical division, First Nation Pharmaceuticals .
  • Combining First Nation Group\xe2\x80\x99s proven capabilities in healthcare delivery with expertise from key leaders in the pharmaceutical industry, this newly created division will be providing pharmaceuticals to Government and limited commercial markets to deliver the best healthcare solutions to our customers.\nFirst Nation Pharmaceuticals will leverage First Nation Group\xe2\x80\x99s expansive distribution, procurement, and data analytics capabilities to revolutionize the purchasing of generic pharmaceuticals tailored specifically to the needs of government customers.
  • These key advantages will allow First Nation Pharmaceuticals to improve partners\xe2\x80\x99 insights and market share, delivering greater access and better pricing to critically needed products for their customers.\n\xe2\x80\x9cWe\xe2\x80\x99ve paired First Nation Group\xe2\x80\x99s core capabilities and strengths with well-known industry experts to develop the new pharmaceutical division, accelerating our ability to scale production and distribution quickly,\xe2\x80\x9d said Cheryl Nilsson, Owner and Chief Executive Officer of First Nation Group.
  • \xe2\x80\x9cThis new division is an organic growth strategy that gives us the opportunity take a more comprehensive approach in treating the whole patient with multiple therapies and pharmacological treatments.\xe2\x80\x9d\nFirst Nation Pharmaceuticals has appointed the most trusted and influential industry leaders to pilot the pharmaceuticals expansion, naming Stephen Flannery as the First Nation Pharmaceuticals President.

Eurofins Supports Reopening of UK Travel With Launch of Affordable Day 2 & 8 Testing Services

Thursday, May 13, 2021 - 1:05pm

b'Eurofins Covid Testing Services Ltd (ECTS) are now officially an approved government provider for day 2 and day 8 PCR testing.

Key Points: 
  • b'Eurofins Covid Testing Services Ltd (ECTS) are now officially an approved government provider for day 2 and day 8 PCR testing.
  • ECTS ensures that PCR testing is fast, reliable, affordable and available to all through easy to use, UKAS accredited, government approved, home testing kits.\nECTS recognises the importance of testing in the fight against COVID-19.
  • These tests support airline, travel and tourism industries by facilitating travel and removing the barrier of expensive testing.
  • All Eurofins test-at-home PCR kits (Test to Reassure, Test to Depart and Test to Release) can be ordered direct from the website .

Spacelabs Healthcare Partners With Masimo to Bring Advanced Measurements to Spacelabs Patient Monitors

Thursday, May 13, 2021 - 1:00pm

View the full release here: https://www.businesswire.com/news/home/20210513005074/en/\n\xe2\x80\x9cWe are pleased to extend our partnership with Masimo as an important element of our mission to empower the care team to achieve superior outcomes,\xe2\x80\x9d said Spacelabs President Shalabh Chandra.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210513005074/en/\n\xe2\x80\x9cWe are pleased to extend our partnership with Masimo as an important element of our mission to empower the care team to achieve superior outcomes,\xe2\x80\x9d said Spacelabs President Shalabh Chandra.
  • These forward-looking statements include, among others, statements regarding the potential effectiveness of SET\xc2\xae, rainbow SET\xc2\xae, NomoLine\xc2\xae, SedLine\xc2\xae, and O3\xc2\xae.
  • All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today\'s date.

Second Sight Medical Products Announces Year Three NIH Funding of Its Orion Study

Thursday, May 13, 2021 - 11:00am

The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial.

Key Points: 
  • The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial.
  • This NIH notice of grant award follows the reporting by the Company of promising two-year data from the Orion Trial on May 12, 2021.
  • A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston.
  • No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.